Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8P1KS
|
|||
| Drug Name |
Zilovertamab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 2 | [1] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [2] | ||
| Company |
Oncternal Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neurotrophic tyrosine kinase ROR1 (ROR1) | Target Info | . | [3] |
| KEGG Pathway | Wnt signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03088878) A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05156905) A Phase 1b Trial Investigating Docetaxel Combined With Cirmtuzumab in Patients With Metastatic Castration Resistant Prostate Cancer. U.S.National Institutes of Health. | |||
| REF 3 | The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.